This observational study aims to detect levels of iron, alpha-synuclein, and soluble lymphocyte activation gene 3 in acute ischemic stroke patients. And to see expressions of iron, alpha-synuclein, and lymphocyte activation gene 3 in the brain tissue of ischemic rats. The main questions it aims to answer are: * Is there an association between iron and alpha-synuclein accumulation in ischemic stroke? * Is there any change in soluble lymphocyte activation gene levels in ischemic stroke and if these levels are related to stroke severity and infarction size? . Can soluble lymphocyte activation gene levels be used as an early biomarker to diagnose ischemic stroke?
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Iron levels
Timeframe: 6 months
Alpha-synuclein levels
Timeframe: 6 months
Levels of Soluble lymphocyte activation gene-3
Timeframe: 6 months
levels of iron, alpha-synuclein, and soluble lymphocyte activation in relation to stroke severity and infarction size
Timeframe: 6 months
Iron levels in brain of rats
Timeframe: 2 months
Levels of Alpha-synuclein expression in brain of rats
Timeframe: 2 months
Levels of Lymphocyte activation gene-3 expression in brain of rats
Timeframe: 2 months